'Unhappiest' Job Sector in America Named in New Study
Known workforce management platform Deputy released its third annual Shift Pulse Report last month, analyzing more than 1.5 million survey results from data collected between April 2024 and April 2025.
The study included a new metric called the Net Happiness Score, which was determined by asking workers to share their personal sentiments about their respective jobs.
Respondents were able to share if they felt "good" or "amazing" about their work or if they were unhappy with their current setup, for one reason or another.
One job sector stood above the rest as the "unhappiest" in America. Results pointed to those working in pharmacies as having the worst Net Happiness Score, with just 13.94 percent of pharmacy workers giving a positive assessment.
The next three on the unhappiest list were those who worked in delivery and postal services, animal health, and medical clinics.
Conversely, the happiest workers were those who worked in tobacco, e-cigarette and marijuana stores. The industry got a phenomenal happiness score of 91.87 percent.
Other job sectors ranking high in the Net Happiness Score were catering businesses, coffee shops and, surprisingly, dental work.
The data also identified the happiest workers by state.
South Carolina, Virginia, and Utah were the top three in that regard. On the other hand, those working in North Dakota, New Mexico and Vermont gave the lowest scores.
However, happiness obviously goes far beyond work and padding one's bank account. Some studies have debunked one huge myth about man's pursuit of happiness.'Unhappiest' Job Sector in America Named in New Study first appeared on Men's Journal on Jul 8, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Boston Scientific Stock Outlook: Is Wall Street Bullish or Bearish?
Boston Scientific Corporation (BSX), headquartered in Marlborough, Massachusetts, develops, manufactures, and markets medical devices for use in various interventional medical specialties globally. With a market cap of $157.9 billion, the company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, and more. Shares of this medTech giant have outperformed the broader market over the past year. BSX has gained 41.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 16.6%. In 2025, BSX stock is up 17.5%, surpassing the SPX's 7.8% rise on a YTD basis. More News from Barchart With UnitedHealth Under DOJ Investigation, Should You Buy, Sell, or Hold UNH Stock Now? Trump Won't Take Away Tesla's Subsidies. Does That Make TSLA Stock a Safe Buy Here? Can AMD Stock Hit $210 in 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Zooming in further, BSX's outperformance is also apparent compared to the iShares U.S. Medical Devices ETF (IHI). The exchange-traded fund has gained about 9% over the past year. Moreover, BSX's double-digit gains on a YTD basis outshine the ETF's 2.3% gains over the same time frame. BSX's strong performance can be credited to its robust product portfolio and dedicated global team. Key achievements in the second quarter include FDA approval for expanding the FARAPULSE PFA System, initiation of the ReMATCH IDE trial, and securing CE Mark for the WATCHMAN FLX Pro device in Europe. The company also finalized the acquisitions of Intera Oncology and SoniVie, enhancing its offerings in liver cancer and hypertension treatment technologies. On Jul. 23, BSX shares closed up more than 4% after reporting its Q2 results. Its adjusted EPS of $0.75 beat Wall Street's expectations of $0.72. The company's revenue was $5.1 billion, exceeding Wall Street forecasts of $4.9 billion. The company expects full-year adjusted EPS in the range of $2.95 to $2.99. For the current fiscal year, ending in December, analysts expect BSX's EPS to grow 18.7% to $2.98 on a diluted basis. The company's earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters. Among the 30 analysts covering BSX stock, the consensus is a 'Strong Buy.' That's based on 27 'Strong Buy' ratings, two 'Moderate Buys,' and one 'Hold.' This configuration is more bullish than two months ago, with 26 analysts suggesting a 'Strong Buy.' On Jul. 24, Raymond James Financial, Inc. (RJF) analyst Jayson Bedford maintained a 'Buy' rating on BSX with a price target of $124, implying a potential upside of 18.2% from current levels. The mean price target of $124.53 represents an 18.7% premium to BSX's current price levels. The Street-high price target of $140 suggests an ambitious upside potential of 33.4%. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
33 minutes ago
- Yahoo
RFK Jr. says cancer screenings are too 'woke' now. As an actual doctor, I disagree.
A 6-centimeter mass. These are the words that shattered my patient's heart, but ultimately gave her a chance at saving and prolonging her life. Weeks earlier, without any worries about her health, she had seen a doctor for a checkup. Following the U.S. Preventive Services Task Force recommendations, her doctor found out she was a former smoker and ordered a scan. Lung cancer was found, which is how she ended up in my hospital for chemotherapy and immunotherapy. Without the task force guidelines, my patient's primary care doctor may not have ordered this scan, and her cancer may not have been caught before it spread to Stage 4, or it was uncurable. The task force has released screening recommendations for patients over the past 40 years that have caught infections, detected cancers and otherwise saved lives countless times. However, it is now reported that Health and Human Services Secretary Robert F. Kennedy Jr. is considering removing and replacing all 16 expert members of this task force for purely political and culture war reasons. This would be a disaster for public health. RFK Jr. thinks preventing curable disease is too 'woke' The Preventive Services Task Force is tasked with providing screening recommendations for finding diseases before they become deadly. These guidelines are evidence-based and updated frequently as new scientific studies are released. Primary care doctors rely on these as they approach which diagnostic tests are most impactful and highest yield for their patients. Insurance companies use the task force's recommendations to know what studies to cover. Their work is important and essential. But we'll be in danger if RFK Jr. wants to upend this institution. Opinion: RFK Jr. is an unserious man. But his misinformed vaccine policy will be deadly. He has already done it once. In June, Kennedy fired all 17 members of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, a committee that makes recommendations on vaccine schedules, for reasons that made little sense. He replaced them with known vaccine skeptics, hampering both sound scientific work and public trust in the organization. This, by the way, at a time when measles cases in the U.S. are at their highest in 30 years. Now it's reported that Kennedy might make these removals within the Preventive Services Task Force because the members are too "woke.' Don't make America backward again in public health Keep in mind, these are individuals who are recommending things like cervical cancer screening is good, or look for post-partum depression in pregnant persons. Opinion: I'm a doctor. Trump's crusade against universities undermines the future of your health. These are sound recommendations that should be noncontroversial. What is woke in that? Some point to things like the word choice of 'persons' instead of 'women'? Don't be a snowflake, and get over yourself. These are important recommendations that are meant to reach all Americans. Opinion alerts: Get columns from your favorite columnists + expert analysis on top issues, delivered straight to your device through the USA TODAY app. Don't have the app? Download it for free from your app store. Even if he doesn't go through with this purge, RFK Jr. is instilling a distrust in our expert medical and scientific institutions. If he does go through with it, he will undermine the pillar of public health that is preventative services at the same time that another pillar, access to care for the vulnerable, has been hacked away at by the Medicaid cuts in the Big Beautiful Bill. Taking these actions will not make America healthy again. It'll make America backward again in public health, and backward in the fight against cancer and disease. We need to sound the alarm to stop all these actions that are harming our fellow Americans. Dr. Thomas K. Lew is an assistant clinical professor of Medicine at the Stanford University School of Medicine and an attending physician of Hospital Medicine at Stanford Health Care Tri-Valley. All expressed opinions are his own. Follow him on X: @ThomasLewMD You can read diverse opinions from our USA TODAY columnists and other writers on the Opinion front page, on X, formerly Twitter, @usatodayopinion and in our Opinion newsletter. This article originally appeared on USA TODAY: Kennedy is making a culture war out of cancer prevention | Opinion Solve the daily Crossword
Yahoo
44 minutes ago
- Yahoo
Pharma interest can plug NIH funding gap: Illumina CEO
Genetic sequencing company Illumina (ILMN) has had a rough few years. It has battled activist investors, faced off with the Federal Trade Commission, and, most recently, agreed to a $9.8 million settlement with the Department of Justice over a cybersecurity breach. To add to the pile: sanctions in China and the Trump administration cutting National Institutes of Health (NIH) funding, which the company relies heavily on for clinical research. The numbers don't lie. The stock is down more than 21% in the past year and sank more than 11% in after-hours trading Thursday after the company reported an earnings miss for the second quarter. The company reported $1.06 billion in revenues compared to expected revenues of $1.05 billion. Adjusted earnings per share came in at $1.19 compared to estimates of $1.01. But CEO Jacob Thaysen told Yahoo Finance he remains positive about the company's near-term growth. Why? Because, in part, pharmaceutical companies can provide a new market. "Now, we're shifting from small things to really big programs. Some of the things making up for the reduction from the NIH is kind of indirect, but pharma is getting more interest in these big programs," he said, noting that 15% of the company is exposed to government research funding. "It's not only about sequencing itself, but really using massive amounts of data ... to really identify new drug targets and understand a disease," Thaysen said. The idea to use patient data to help the pharmaceutical world was also identified by 23andMe, which recently came out of bankruptcy through a nonprofit led by founder Anne Wojcicki. Thaysen said that unlike 23andMe, which he has worked with, his company is not going to pursue drug development on its own. "We have a lot of pharma companies that are very excited to work with us," he said. In addition to genetic testing of patient samples, the company is looking at growing in the preventative side of care with cancer screenings. The oncology business, Thaysen said, will have healthy growth over the next 10 or so years. China China banned importations of the San Diego-based company's sequencing machines earlier this year as part of its retaliatory actions to Trump's tariff war. Thaysen said he is working with regulators to try to reverse that, but "in the meantime, that business is declining, and we are expecting it to be flat." In fact, though China has historically been about 10% of the company's business, it contributed to half of the decline in earnings this past week. "China was never a huge part of Illumina's business. When it was the largest, it was just around 10%. We're down to 5% of the business," Thaysen told Yahoo Finance. But because of the tariff war and China's goals to boost its domestic innovation market, Illumina has faced a setback in its market power there from local competition. "As soon as there is a Chinese alternative that is good enough, then you will see that the Chinese government is pushing for the Chinese population, the Chinese companies to use that technology," Thaysen said. He added that even with the increased competition, China is an appealing market to remain in. Analysts are still waiting to see more progress on Illumina's return to growth. Jefferies analyst Tycho Peterson said in a note to clients that the firm will reiterate its Hold rating until things settle: "While the clinical traction is encouraging, we view clarity on near-term headwinds (A&G, China, Roche) and a path to sustainable HSD growth as key to a more constructive view. Reiterate Hold." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
